MRNA vaccine aims to prevent shingles in older adults
NCT ID NCT07205796
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants and will measure immune responses and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Herpes Zoster IN001 mRNA Vaccine (IN001)
- What this could lead to
- If successful, this could lead to a new mRNA-based shingles vaccine that is safer or more effective than current options.
- What could go wrong
- This is an early phase 2 trial with only 480 participants, so results may not apply to everyone. The vaccine could cause side effects or fail to show strong enough immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
- Shingles in cancer patients: a hidden cost burden?
- Shingles vaccine protection tested over 6 years in 24,740 adults
- New gel promises shingles pain relief in minutes
- Shingles shot may shield brain: 33,000 seniors test dementia link
- New shingles vaccine trial aims to protect millions over 40